Skip to main content
SpringerLink
Log in

Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series

  • Toxicology Observation
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Introduction

Dabigatran, an oral direct thrombin inhibitor, is FDA approved for the prevention of stroke in patients with nonvalvular atrial fibrillation. No agent exists for the reversal of dabigatran-related major bleeding. Prothrombin complex concentrate (PCC) has been studied in reversal but was not shown to affect the surrogate markers of bleeding such as the thrombin time, ecarin clotting time, or activated partial thromboplastin time (aPTT). Recombinant factor VIIa (rFVIIa) may provide benefit in patients with life-threatening or major bleeding; however, it has not been studied in dabigatran-related bleeding. PCC and rFVIIa are agents utilized at our institution for major bleeding in patients receiving anticoagulant therapy. Due to the high cost and thrombogenic risk of both rVIIa and PCC and lack of a clear reversal strategy, we reviewed the management of all reported cases of dabigatran-related bleeding.

Methods

This was a retrospective chart review of patients admitted to UMass Memorial Medical Center with a bleeding event and also receiving dabigatran therapy.

Results

Eleven patients on dabigatran admitted for bleeding were identified. Seven were admitted for an intracranial hemorrhage (ICH) and four for a gastrointestinal hemorrhage (GIH). The baseline characteristics are as follows: mean age was 74.55 years (range, 63–89), and seven were male. Admission mean hemoglobin was 11.88 g/dl (range, 6.1–18), mean international normalized ratio (INR) was 2.2 (range, 1.1–7.1), and mean aPTT was 42.21 s (range, 36–81.4). Interventions received included fresh frozen plasma (n = 6), platelets (n = 3), packed red blood cells (n = 4), rFVIIa (n = 2), intravenous fluids (n = 10), surgical intervention (n = 3), and dialysis (n = 2). No patients received PCC. Four patients survived in the ICH group, and four patients survived in the GIH group.

Conclusion

Reversal strategies for dabigatran-related bleeding events at our institution are highly variable. Intracranial hemorrhage in patients on dabigatran was associated with 43 % mortality. Patients with severe dabigatran-related bleeding may benefit from a standardized approach to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Boriani G, Diemberger I (2012) Editorial. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest 142(6):1368–1370

    Article  PubMed  Google Scholar 

  2. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e531S–e575S

    CAS  PubMed Central  PubMed  Google Scholar 

  3. (2012) Product information: PRADAXA® oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim Pharmaceuticals, Inc. (per FDA), Ridgefield

  4. U.S. Food and Drug Administration (2012) FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa. U.S. Food and Drug Administration (FDA), Silver Spring. http://www.fda.gov/drugs/drugsafety/ucm326580.htm Accessed 4 Nov 2012

  5. Wood S (2011) Dabigatran: 260 fatal bleeds since approval worldwide. Theheart.org. [Clinical conditions > Arrhythmia/EP > Arrhythmia/EP]. http://www.theheart.org/article/1314809.do. Accessed 1 Mar 2013

  6. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    Article  CAS  PubMed  Google Scholar 

  7. Schattner A, Kozak N, Friedman J (2013) Case report: fatality in a patient treated with dabigatran. Am J Emerg Med 31(2):443.e1–443.e2

    Article  Google Scholar 

  8. Warkentin TE, Margetts P, Connolly SJ et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9):2172–2174

    Article  CAS  PubMed  Google Scholar 

  9. Cano EL, Miyares MA (2012) Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. J Geriatr Pharmacother 10:160–163

    Article  Google Scholar 

  10. Dy EA, Shiltz DL (2012) Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 46(7–8):e18

    Article  PubMed  Google Scholar 

  11. Legrand M, Mateo J, Aribaud A et al (2011) The use of dabigatran in elderly patients. Arch Intern Med 171(14):1285–1288

    Article  PubMed  Google Scholar 

  12. Garber ST, Sivakumar W, Schmidt RH (2012) Neurosurgical complications of direct thrombin inhibitors—catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 116(5):1093–1096

    Article  PubMed  Google Scholar 

  13. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579

    Article  CAS  PubMed  Google Scholar 

  14. Zhou W, Schwarting S, Illanes S et al (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42:3594–3599

    Article  PubMed  Google Scholar 

  15. Ageno W, Gallus AS, Wittkowsky A et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e44S–e88S

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Dager WE, Gosselin RC, Roberts J (2013) Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 41:1–5

    Article  Google Scholar 

  17. Chen BC, Viny AD, Garlich FM et al (2012) Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 50:854–857

    Article  CAS  Google Scholar 

  18. Van Ryn J, Stangier J, Haetter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127

    Article  PubMed  Google Scholar 

  19. Escolar G, Arellano E, Carne X, et al. (2012) Evaluation of the potential action of coagulation factors concentrates in the reversal of the antithrombotic action of new oral anticoagulants: studies ex vivo in blood samples from healthy volunteers. Clinicaltrials.gov. www.clinicaltrials.gov/ct2/show/NCT01478282. Accessed 1 Mar 2013

  20. Pernod G (2011) Reversion of the anticoagulant effect of the new antithrombotic agents anti-Xa and anti-IIa by specific and non-specific haemostatic drugs: an ex-vivo study in healthy volunteers. Clinicaltrials.gov. www.clinicaltrials.gov/ct2/show/NCT01210755. Accessed 1 Mar 2013

  21. van Ryn J, Litzenburger T, Waterman A et al (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57(14):E1130 (abstr)

    Article  Google Scholar 

Download references

Conflict of Interest

The authors of this paper have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this study.

Author information

Authors and Affiliations

  1. UMass Memorial Medical Center, 55 Lake Ave. N, Worcester, MA, 01655, USA

    Britney Ross, Kristen Ditch & Maichi Tran

  2. New York-Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street, New York, NY, 10032, USA

    Melissa A. Miller

Authors
  1. Britney Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa A. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristen Ditch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maichi Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Britney Ross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ross, B., Miller, M.A., Ditch, K. et al. Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series. J. Med. Toxicol. 10, 223–228 (2014). https://doi.org/10.1007/s13181-013-0364-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-013-0364-1

Keywords

Search

Navigation